• GSK Canada completed price negotiations with the pan-Canadian Pharmaceutical Alliance for Blenrep in relapsed or refractory multiple myeloma.
• Talks resulted in a Letter of Intent, a step toward public drug-plan coverage across Canada.
• Funding agreements still require separate decisions by provincial and territorial plans under their own timelines.
• Blenrep was cleared by Health Canada in July 2025 in two combination regimens, including use as early as first relapse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via CNW (Ref. ID: 202609220700CANADANWCANADAPR_C4940) on September 22, 2026, and is solely responsible for the information contained therein.